PMID: 18712096Aug 21, 2008Paper

Module of hypercoagulation as a biomarker for estimation of hemostasis risk factor of thrombosis, determination of an individual antiaggregant dose and the way of its use in patients with arterial hypertension

Likars'ka sprava
S M Tolstopiatov

Abstract

12 patients with stage II arterial hypertantion have been administered a complex therapy including antihypertensive, hypocholesterolemic (statines), and antiagregant (aspirin, acelisin) agents as a preventive maintenance of vascular complications (stroke, myocardial infarction). Optimization of individual treatment was established by controlling parameters of the integrated indicator of the coagulation cascade of whole blood. This indicator is called the coagulation module (CM). In a clinical practice this biomarker favours qualitative assessment of disorders of the coagulation potential and degree of its dysfunction. Patients having a high risk factor (CM+VI-VIII degree) have began their treatment with intramuscular administration of acelisin in individual doses within 4-6 days.

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.